SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.

Other languages Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Equities

002603

CNE1000015S0

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-04-25 EDT			5-day change	1st Jan Change
19.58 ^CNY	+0.67%		+1.40%	-15.13%

04-26	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-26	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26
Yiling Pharmaceutical Gets Nod for China Clinical Trial of Tracheobronchitis Drug	12-06
Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4%	11-23
Yiling Pharmaceutical Gets Nod to Trial Huoxia Cold Granules	11-17
Yiling Pharmaceutical Presents Clinical Data on Cardiovascular Drug at Beijing Conference	11-17
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26
Yiling Pharmaceutical Gets Green Light to Trial Acute Myeloid Leukemia Drug	23-10-24
Yiling Pharmaceutical Gets Greenlight to Trial G201-Na Capsules	23-10-12
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 17 July 2023	23-07-11
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022	23-05-22
Yiling Pharma's Hypertension Drug Passes Regulatory Evaluation in China	23-05-15
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022	23-04-26
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25
Yiling Pharma Wins Nod to Trial Prostate Cancer Drug	23-04-05
Yiling Pharma Unit Gets Marketing Rights of Rujietai Capsules	23-03-02
Shijiazhuang Yiling Pharma Appoints Founder as Honorary Chairman	23-02-28
Yiling Pharma Gets Regulatory Nod for Traditional Chinese Medicine	23-02-03
Yiling Pharma’s Antibiotic Passes Consistency Test	23-02-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Equities

002603

CNE1000015S0

Other languages

Filters